Incidence of Hemocompatibility Events With or Without Aspirin in Patients With CH-VAD

The goal of this observational study is to investigate the impact of oral warfarin anticoagulation combined with or without aspirin on the incidence of non-surgical hemocompatibility-related adverse events (HRAEs) and survival in advanced heart failure patients after implantation of the fully magnetic levitation left ventricular assist device (CH-VAD). The main question it aims to answer is : The incidence of non-surgical HRAEs and survival treated with oral warfarin anticoagulation combined with or without aspirin in Chinese CH-VAD implanted advanced heart failure patients. CH-VAD has been approved in China for the treatment of patients with advanced heart failure.

NCT Number	NCT07343102
Lead Sponsor	China National Center for Cardiovascular Diseases Collaborators: Zhejiang Provincial People's Hospital, Sichuan Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, Shanghai Zhongshan Hospital, Jiangsu Provincial People's Hospital, Ruijin Hospital, Sir Run Run Shaw Hospital, Henan Provincial Chest Hospital, Wuhan Asia Heart Hospital, First Affiliated Hospital of Zhejiang University, Second Hospital of Jilin University, Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions	Hemocompatibility-related Adverse Event
Enrollment	220 participants
Start Date	2022-08-01
Primary Completion	2025-11-20 (estimated)
Study Completion	2025-11-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-15